Physician profile
Alan Y Lo
NPI 1982683637
$11,180.61
in general payments reported to CMS, 2019-2025
47 companies · $1,457 in 2025
The $1,457 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,948 · 2020: $2,313 · 2021: $1,844 · 2022: $1,251 · 2023: $1,189 · 2024: $1,178 · 2025: $1,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,824.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,101.78 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Lilly USA, LLC | $1,037.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $954.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $952.73 | 2019-2025 | Jardiance |
| Pfizer INC. | $726.76 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $518.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $435.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $386.24 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $370.22 | 2019-2023 | Livalo, Seglentis |
| Astellas Pharma US INC | $332.19 | 2019-2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $319.08 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $272.68 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Abbott Laboratories | $264.79 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $261.33 | 2019-2025 | |
| Amgen INC. | $243.25 | 2019-2025 | Otezla, Repatha, Otezla |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $169.84 | 2020-2025 | Nexletol |
| Ibsa Pharma INC. | $155.71 | 2020-2025 | Tirosint, Licart, Flector |
| Medicure Pharma INC. | $149.50 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $116.66 | 2019-2022 | |
| Amarin Pharma, INC. | $113.77 | 2019-2021 | |
| Radius Health, INC. | $107.93 | 2019-2020 | |
| Eisai INC. | $103.93 | 2020-2022 | |
| Impel Pharmaceuticals INC. | $98.86 | 2023 | Trudhesa |
| Grifols USA, LLC | $97.00 | 2020-2023 | Prolastin-C Liquid |
| Sanofi Pasteur INC. | $91.79 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.97 | 2021-2024 | Vpriv |
| Phathom Pharmaceuticals, INC. | $60.70 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $59.69 | 2020-2025 | Camzyos |
| Allergan, INC. | $59.58 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.57 | 2022 | |
| Dexcom, INC. | $51.87 | 2020-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $49.62 | 2023-2025 | Cologuard Collection Kit |
| Alfasigma USA, INC. | $45.67 | 2020-2022 | |
| Edwards Lifesciences Corporation | $44.52 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Idorsia Pharmaceuticals US INC | $43.40 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $33.37 | 2020 | |
| Nestle Healthcare Nutrition INC. | $25.21 | 2021 | |
| Ethicon INC. | $21.55 | 2023 | Monarch Platform |
| Biohaven Pharmaceuticals, INC. | $21.36 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $20.59 | 2020 | |
| Impel Pharmaceuticals LLC | $19.87 | 2025 | Trudhesa |
| Shield Therapeutics INC | $18.41 | 2023 | Accrufer |
| Sumitomo Pharma America, INC. | $17.73 | 2024 | Gemtesa |
| Genentech USA, INC. | $16.02 | 2021 | |
| Almatica Pharma LLC | $14.99 | 2024 | Loreev Xr |
| Hologic Sales and Service, LLC | $14.79 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.